Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 63, Number 6, September 28, 2004
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrow, S. A.
Right arrow Articles by Metz, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrow, S. A.
Right arrow Articles by Metz, L. M.
Related Collections
Right arrow Multiple sclerosis
Right arrowRelated Article
NEUROLOGY 2004;63:1079-1080
© 2004 American Academy of Neurology
Brief Communications

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

S. A. Morrow, MD, C. A. Stoian, MD MSc, J. Dmitrovic, MSc, S. C. Chan, PhD and L. M. Metz, MD FRCPC

From the Department of Clinical Neurosciences (Dr. Morrow), University of Western Ontario, London, Ontario; and the Department of Clinical Neurosciences (Drs. Stoian and Metz) and Departments of Pharmacology and Therapeutics/Pathology and Laboratory Medicine (Mr. Dmitrovic and Dr. Chan), University of Calgary, Calgary, Alberta, Canada.

Address correspondence and reprint requests to Dr. Luanne Metz, Foothills Hospital, 1403–29th Street NW, Calgary, Alberta, T2N 2T9; e-mail: lmetz{at}ucalgary.ca

Oral prednisone 1might be a convenient, inexpensive alternative to IV methylprednisolone (IVMP) if the bioequivalent dose was known. We compared the total amount of steroid absorbed after 1250 mg oral prednisone vs 1 gram IVMP in 16 patients with multiple sclerosis (MS). At 24 hours, the mean area under the concentration-time curve (AUC), the main component of bioavailability, did not differ between groups (p = 0.122). This suggests that the amount of absorbed corticosteroid is similar after either steroid at these doses.

Received April 7, 2004. Accepted in final form June 9, 2004.

See Commentary, page 945


Related Article

September 28 Highlight and Commentary
Neurology 2004 63: 945. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 FASEB J.Home page
S. Tsutsui, D. Vergote, N. Shariat, K. Warren, S. S. G. Ferguson, and C. Power
Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and {beta}-arrestin-1 in monocytoid cells
FASEB J, March 1, 2008; 22(3): 786 - 796.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
T J Murray
Diagnosis and treatment of multiple sclerosis.
BMJ, March 4, 2006; 332(7540): 525 - 527.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. Strupp and L. M. Metz
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
Neurology, March 22, 2005; 64(6): 1100 - 1100.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis
Michael Strupp
Neurology Online, 18 Nov 2004 [Full text]
Reply to Strupp
Luanne M Metz
Neurology Online, 18 Nov 2004 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.